CTSO says DrugSorb-ATR shows strong clinical results
CTSO says DrugSorb-ATR has strong clinical and real-world data as it advances blood purification technologies, with international sales, improved gross margins, early benefits from restructuring in Germany, and plans targeting a 2027 FDA pathway.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.